SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

Giant Cell Myocarditis: Scoping Review with ☸️SAIMSARA.

Cardiac & Vascular Health icon

Cardiac & Vascular Health

Issue 1, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsara4bbcdf64

Editorial note
• Last update: 2026-05-28 13:06:20
What is this paper about
Giant cell myocarditis is rare, but the evidence map shows why it should never be treated as a diagnostic afterthought: survival depends on early biopsy, rapid combination immunosuppression, and timely escalation to mechanical support or transplantation. The full review distills 169 references into a practical map of prognosis, arrhythmia risk, cardiac sarcoidosis overlap, relapse surveillance, and the unresolved gaps that still shape real-world management.
Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.
Found an issue in this paper? Email admin@saimsara.com


Abstract: To synthesize the original-study evidence on GCM, emphasizing clinical phenotype, prognosis, diagnostic approaches, mechanistic biology, treatment strategies, and research gaps relevant to the query “giant cell myocarditis.”. The review uses 169 references and builds its evidence map from 300 original studies with 28395 total participants/sample observations (topic-deduplicated ΣN). The evidence consistently portrays GCM as a rare but aggressive immune-mediated myocarditis where early tissue diagnosis and prompt combination immunosuppression are the dominant determinants of survival, with historical cohorts reporting 89% death or transplant and median survival of 5.5 months improving to 42% 5-year transplant-free survival in contemporary series. Across studies, cyclosporine-based regimens, mechanical circulatory support, and heart transplantation emerge as the central pillars of management, while life-threatening ventricular arrhythmias exceeding 50% at 5 years reinforce the need for sustained rhythm surveillance. Diagnostic uncertainty, particularly the boundary with cardiac sarcoidosis, remains a recurrent challenge that molecular and advanced imaging tools may help resolve. Because most evidence derives from retrospective case-level data, the main signal should guide practice cautiously rather than as proof of effect. Prospective multicenter registries with standardized diagnostic criteria and immunosuppression protocols represent the most pressing research priority.

Keywords: Giant cell myocarditis; Fulminant myocarditis; Endomyocardial biopsy; Immunosuppressive therapy; Cardiac sarcoidosis; Heart transplantation; Mechanical circulatory support; Ventricular arrhythmias; Cardiogenic shock; Cardiac magnetic resonance

Review Stats

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (169)

Unlock the full paper to view the complete Reference Index.

Article views: —
Follow us

© 2026 SAIMSARA Journal Impressum Published by ML in Health Science GbR